Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23074
Title: Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury.
Authors: Beyer, Leonie;Nitschmann, Alexander;Barthel, Henryk;van Eimeren, Thilo;Unterrainer, Marcus;Sauerbeck, Julia;Marek, Ken;Song, Mengmeng;Palleis, Carla;Respondek, Gesine;Hammes, Jochen;Barbe, Michael T;Onur, Özgür;Jessen, Frank;Saur, Dorothee;Schroeter, Matthias L;Rumpf, Jost-Julian;Rullmann, Michael;Schildan, Andreas;Patt, Marianne;Neumaier, Bernd;Barret, Olivier;Madonia, Jennifer;Russell, David S;Stephens, Andrew W;Roeber, Sigrun;Herms, Jochen;Bötzel, Kai;Levin, Johannes;Classen, Joseph;Höglinger, Günter U;Bartenstein, Peter;Villemagne, Victor;Drzezga, Alexander;Seibyl, John;Sabri, Osama;Brendel, Matthias
Affiliation: Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany
Molecular Neuroimaging, inviCRO, New Haven, CT, USA
Max- Planck-Institute of Human Cognitive and Brain Sciences, Leipzig, Germany
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Department of Psychiatry, University Hospital Cologne, Cologne, Germany
Center for Memory Disorders, University Hospital Cologne, Cologne, Germany
Cognitive Neuroscience, Institute for Neuroscience and Medicine (INM-3), Research Centre Juelich, Juelich, Germany
Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Neurology, Technische Universität München, Munich, Germany
Department of Neurology, Hannover Medical School, Hannover, Germany
Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany
Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany
InviCRO, LLC, Boston, MA, USA
Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Juelich GmbH, Juelich, Germany
Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne, Germany
Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany
LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany
Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
Department of Nuclear Medicine, University Hospital of Munich LMU Munich, Marchioninstraße 15, 81377, Munich, Germany
Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany
Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany
Center for Memory Disorders, University Hospital Cologne, Cologne, Germany
Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
Life Molecular Imaging GmbH, Berlin, Germany
Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany
Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany
Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany
Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
Issue Date: 21-Apr-2020
EDate: 2020-04-21
Citation: European journal of nuclear medicine and molecular imaging 2020; online first: 21 April
Abstract: Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG). Twenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, multi-system atrophy, Parkinson's disease, multi-system atrophy, Parkinson's disease, frontotemporal dementia) and received a dynamic [18F]PI-2620 tau-PET (0-60 min p.i.) and static [18F]FDG-PET (30-50 min p.i.). Regional standardized uptake value ratios of early-phase images (single frame SUVr) and the blood flow estimate (R1) of [18F]PI-2620-PET were correlated with corresponding quantification of [18F]FDG-PET (global mean/cerebellar normalization). Reduced tracer uptake in cortical target regions was also interpreted visually using 3-dimensional stereotactic surface projections by three more and three less experienced readers. Spearman rank correlation coefficients were calculated between early-phase [18F]PI-2620 tau-PET and [18F]FDG-PET images for all cortical regions and frequencies of disagreement between images were compared for both more and less experienced readers. Highest agreement with [18F]FDG-PET quantification was reached for [18F]PI-2620-PET acquisition from 0.5 to 2.5 min p.i. for global mean (lowest R = 0.69) and cerebellar scaling (lowest R = 0.63). Correlation coefficients (summed 0.5-2.5 min SUVr & R1) displayed strong agreement in all cortical target regions for global mean (RSUVr 0.76, RR1 = 0.77) and cerebellar normalization (RSUVr 0.68, RR1 = 0.68). Visual interpretation revealed high regional correlations between early-phase tau-PET and [18F]FDG-PET. There were no relevant differences between more and less experienced readers. Early-phase imaging of [18F]PI-2620 can serve as a surrogate biomarker for neuronal injury. Dynamic imaging or a dual time-point protocol for tau-PET imaging could supersede additional [18F]FDG-PET imaging by indexing both the distribution of tau and the extent of neuronal injury.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23074
DOI: 10.1007/s00259-020-04788-w
ORCID: 0000-0002-5832-9875
PubMed URL: 32318783
Type: Journal Article
Subjects: Neuronal injury
PET
Perfusion
Tau
[18F]PI-2620
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.